Gelderblom H - Search Results

1

The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.

Opdam FL, Dezentje VO, den Hartigh J, Modak AS, Vree R, Batman E, Smorenburg CH, Nortier JW, Gelderblom H, Guchelaar HJ. Opdam FL, et al. Among authors: gelderblom h. Cancer Chemother Pharmacol. 2013 Mar;71(3):593-601. doi: 10.1007/s00280-012-2034-4. Epub 2012 Dec 11. Cancer Chemother Pharmacol. 2013. PMID: 23228987

2

Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.

Kweekel DM, Gelderblom H, Guchelaar HJ. Kweekel DM, et al. Among authors: gelderblom h. Cancer Treat Rev. 2005 Apr;31(2):90-105. doi: 10.1016/j.ctrv.2004.12.006. Cancer Treat Rev. 2005. PMID: 15847979 Review.

3

Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.

Cremers SC, Papapoulos SE, Gelderblom H, Seynaeve C, den Hartigh J, Vermeij P, van der Rijt CC, van Zuylen L. Cremers SC, et al. Among authors: gelderblom h. J Bone Miner Res. 2005 Sep;20(9):1543-7. doi: 10.1359/JBMR.050522. Epub 2005 May 31. J Bone Miner Res. 2005. PMID: 16059626 Free article.

4

Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.

van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H. van Erp NP, et al. Among authors: gelderblom h. Clin Cancer Res. 2005 Nov 1;11(21):7800-6. doi: 10.1158/1078-0432.CCR-05-1288. Clin Cancer Res. 2005. PMID: 16278402

5

Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.

Steeghs N, Nortier JW, Gelderblom H. Steeghs N, et al. Among authors: gelderblom h. Ann Surg Oncol. 2007 Feb;14(2):942-53. doi: 10.1245/s10434-006-9227-1. Epub 2006 Nov 14. Ann Surg Oncol. 2007. PMID: 17103252 Review.

6

[Long-term beneficial effects of cetuximab in a woman with metastasised rectal carcinoma without expression of the epidermal growth factor receptor].

Kroep JR, Gelderblom H, Collen AF, Nortier JW. Kroep JR, et al. Among authors: gelderblom h. Ned Tijdschr Geneeskd. 2006 Nov 18;150(46):2555-9. Ned Tijdschr Geneeskd. 2006. PMID: 17152334 Dutch.

7

Is rectal administration an alternative route for imatinib?

van Erp NP, Oostendorp RL, Guchelaar HJ, Schellens JH, Gelderblom H. van Erp NP, et al. Among authors: gelderblom h. Cancer Chemother Pharmacol. 2007 Sep;60(4):623-4. doi: 10.1007/s00280-006-0409-0. Epub 2007 Feb 8. Cancer Chemother Pharmacol. 2007. PMID: 17287936 Free article. No abstract available.

8

Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs.

Pander J, Gelderblom H, Guchelaar HJ. Pander J, et al. Among authors: gelderblom h. Expert Opin Pharmacother. 2007 Jun;8(9):1197-210. doi: 10.1517/14656566.8.9.1197. Expert Opin Pharmacother. 2007. PMID: 17563256 Review.

9

Cyclopentenyl cytosine (CPEC): an overview of its in vitro and in vivo activity.

Schimmel KJ, Gelderblom H, Guchelaar HJ. Schimmel KJ, et al. Among authors: gelderblom h. Curr Cancer Drug Targets. 2007 Aug;7(5):504-9. doi: 10.2174/156800907781386579. Curr Cancer Drug Targets. 2007. PMID: 17691910 Review.

10

Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.

van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, Nortier JW, Guchelaar HJ, Baker SD, Sparreboom A. van Erp NP, et al. Among authors: gelderblom h. Clin Cancer Res. 2007 Dec 15;13(24):7394-400. doi: 10.1158/1078-0432.CCR-07-0346. Clin Cancer Res. 2007. PMID: 18094422 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

886 results

Search Page

Filters